Compare · MEDP vs OABI
MEDP vs OABI
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $16.58B, about 26.0x OABI ($636.8M).
- MEDP has been more active in the news (15 items in the past 4 weeks vs 3 for OABI).
- MEDP has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- Medpace Holdings Inc.
- OmniAb Inc.
- Price
- -
- -
- Market cap
- $16.58B
- $636.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 15
- 3
- Recent ratings
- 25
- 5
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest MEDP
- President & CEO Troendle August J. sold $403,176 worth of shares (650 units at $620.27), decreasing direct ownership by 0.12% to 539,894 units (SEC Form 4)
- Innventure Announces Board Leadership Changes to Further Enhance Board Independence and Acceleration of CEO Transition
- Director Kraft Robert O. exercised 3,858 shares at a strike of $84.36 and sold $2,383,511 worth of shares (3,858 units at $617.81) (SEC Form 4)
- President & CEO Troendle August J. sold $2,897,636 worth of shares (4,673 units at $620.08), decreasing direct ownership by 0.86% to 540,544 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)
Latest OABI
- OmniAb to Participate in Upcoming Investor Conferences
- OmniAb Raises 2026 Financial Guidance
- OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
- SEC Form 4 filed by Chief Operating Officer Nwachuku Amechi Ekeke
- VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
- OmniAb to Report Second Quarter 2026 Financial Results on August 6
- SEC Form 3 filed by new insider Nwachuku Amechi Ekeke